Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LIXT

Lixte Biotechnology Holdings Inc

Jun 01 • 02:14PM ET

6.56

+0.31 4.96 %

Healthcare • Biotechnology • USA • Micro • NASD

Today, 8:55 AMLixte Biotechnology pivots into AI energy infrastructure equipment and services platform

Peers: BYSI CING ESLA IBIO IBO IMA IMMP PDSB TIL TCRX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.12	Insider Own	5.92%	Shs Outstand	12.38M	Perf Week	11.56%
Market Cap	81.23M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	11.65M	Perf Month	87.43%
Enterprise Value	80.27M	PEG	-	EPS next Q	-	Inst Own	5.92%	Short Float	0.60%	Perf Quarter	123.89%
Income	-7.31M	P/S	-	EPS this Y	-	Inst Trans	-7.04%	Short Ratio	1.18	Perf Half Y	55.82%
Sales	0.00M	P/B	9.60	EPS next Y	-	ROA	-116.70%	Short Interest	0.07M	Perf YTD	66.92%
Book/sh	0.68	P/C	24.99	EPS next 5Y	-	ROE	-158.69%	52W High	6.50 0.92%	Perf Year	460.68%
Cash/sh	0.26	P/FCF	-	EPS past 3/5Y	31.98% 15.39%	ROIC	-85.93%	52W Low	0.64 925.00%	Perf 3Y	-0.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.12% 14.15%	Perf 5Y	-76.90%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	22.50%	Oper. Margin	-	ATR (14)	0.65	Perf 10Y	-31.67%
Dividend Ex-Date	-	Quick Ratio	2.78	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	71.01	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.78	EPS Q/Q	37.90%	SMA20	23.87%	Beta	1.29	Target Price	-
Payout	-	Debt/Eq	0.13	Sales Q/Q	-	SMA50	62.46%	Rel Volume	16.02	Prev Close	6.25
Employees	3	LT Debt/Eq	0.06	Earnings	-	SMA200	64.34%	Avg Volume	59.45K	Price	6.56
IPO	Sep 21, 2007	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	706,544	Change	4.96%

Today 08:50AM	LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors (GlobeNewswire)
May-14-26 05:18PM	LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update (GlobeNewswire)
Apr-27-26 02:14PM	LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment (NewMediaWire)
Apr-20-26 03:00PM	LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape (NewMediaWire)
Apr-17-26 03:30PM	Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built (NewMediaWire) +12.11%
03:30PM	Loading…
Apr-13-26 03:30PM	LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference (NewMediaWire)
08:00AM	Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference (GlobeNewswire)
Apr-10-26 03:00PM	Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships (NewMediaWire) +5.17%
Apr-02-26 02:30PM	LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year (NewMediaWire)
Apr-01-26 02:30PM	LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes (NewMediaWire)
Mar-31-26 03:45PM	LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year (GlobeNewswire)
03:00PM	LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials (NewMediaWire)
Mar-27-26 03:30PM	Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies Partnership (NewMediaWire)
Mar-25-26 03:00PM	Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming (NewMediaWire) +10.74%
Mar-23-26 03:00PM	LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape (NewMediaWire)
02:26PM	Loading…
Mar-10-26 02:26PM	LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline (NewMediaWire)
Mar-09-26 03:00PM	LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity Research (NewMediaWire)
Feb-18-26 03:00PM	LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary (NewMediaWire)
08:00AM	LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary (GlobeNewswire)
Feb-12-26 03:00PM	LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy (NewMediaWire)
Feb-10-26 03:00PM	LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment (NewMediaWire) -9.73%
Feb-09-26 03:30PM	LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment (NewMediaWire)
Feb-05-26 02:30PM	Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective (NewMediaWire) -6.21%
Jan-23-26 03:00PM	LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy (NewMediaWire)
Jan-21-26 03:30PM	LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit (NewMediaWire)
08:00AM	DE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE (GlobeNewswire)
Jan-20-26 08:00AM	LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 (GlobeNewswire) -8.43%
Jan-08-26 03:50PM	LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK (NewMediaWire)
Dec-23-25 08:00AM	LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial (GlobeNewswire)
Dec-18-25 09:00AM	Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules (GlobeNewswire)
08:30AM	Loading…
Dec-08-25 08:30AM	LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities (ACCESSWIRE) +7.16%
Dec-03-25 11:00AM	LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology (ACCESSWIRE)
08:00AM	LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers (ACCESSWIRE)
Nov-25-25 08:30AM	LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment (GlobeNewswire) -8.50%
Oct-29-25 08:00AM	LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3 (GlobeNewswire)
Oct-16-25 08:00AM	LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans (GlobeNewswire)
Sep-16-25 08:30AM	LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT) (ACCESSWIRE)
Sep-15-25 05:40PM	LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT) (ACCESSWIRE) -5.08%
Sep-10-25 04:05PM	LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions (GlobeNewswire) +6.25%
Sep-05-25 08:35AM	24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor (Newsfile)
Sep-03-25 08:00AM	LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer (GlobeNewswire) +11.59%
Aug-27-25 08:15AM	24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy (GlobeNewswire)
Aug-25-25 08:05AM	24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets (GlobeNewswire)
Aug-19-25 11:18AM	24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the "Too Much of a Good Thing" Strategy for LB-100 (GlobeNewswire) -8.90%
Aug-18-25 08:00AM	LIXTE Biotechnology Holdings Provides Corporate Update (GlobeNewswire) +6.41%
Aug-14-25 09:06PM	24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025 (GlobeNewswire) -7.95%
08:05AM	24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025 (GlobeNewswire)
Aug-13-25 08:49AM	24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy (GlobeNewswire) -16.29%
07:30AM	LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency (GlobeNewswire)
Jul-16-25 08:05AM	LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements (GlobeNewswire)
Jul-09-25 05:15PM	Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.s $1.5 Million Registered Direct Offering (GlobeNewswire) +8.70% +53.45%
08:05AM	New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials (GlobeNewswire)
Jul-08-25 04:05PM	Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering (GlobeNewswire) +12.95%
02:57PM	Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.s $5.0 Million Private Placement (GlobeNewswire)
Jul-02-25 04:05PM	Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market (GlobeNewswire) +71.19% +40.10%
Jul-01-25 04:15PM	Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market (GlobeNewswire) +30.39%
Mar-31-25 08:30AM	LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 (GlobeNewswire)
Mar-27-25 08:30AM	LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer (GlobeNewswire)
Mar-10-25 08:30AM	New Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active Form (GlobeNewswire)
Feb-25-25 08:30AM	LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer (GlobeNewswire) +15.36%
Feb-14-25 10:43AM	Lixte Biotechnology announces closing of $1.05M registered direct offering (TipRanks)
Feb-13-25 10:35AM	LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.65%
Feb-11-25 08:42AM	LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -15.35%
Feb-10-25 05:00PM	LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement (GlobeNewswire) -7.32%
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Sep-04-24 08:30AM	LIXTE Receives U.S. Patent Issue Notification for Immune Oncology (GlobeNewswire)
Aug-26-24 08:30AM	First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company (GlobeNewswire) +11.12%
Aug-19-24 08:30AM	LIXTE Biotechnology Provides Update On Recent Activities and Developments (GlobeNewswire)
Aug-16-24 08:53PM	LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024 (InvestorPlace)
Aug-15-24 08:30AM	LIXTE Biotechnology Holdings to Present at Two Investor Conferences (GlobeNewswire)
Aug-14-24 10:50PM	Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event (ACCESSWIRE)
Jun-14-24 11:00AM	LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial (GlobeNewswire)
09:30AM	LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial (GlobeNewswire)
Jun-06-24 08:30AM	Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System (GlobeNewswire)
Jun-03-24 08:30AM	LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer (GlobeNewswire) +6.50%
May-20-24 08:30AM	LIXTE Biotechnology Holdings Provides Update on Recent Activities (GlobeNewswire)
May-09-24 01:53PM	LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q1 2024 (InvestorPlace)
May-08-24 09:25AM	LIXTE Biotechnology Co-Sponsoring International Scientific Conference on Therapeutic Over-Activation in Cancer (GlobeNewswire)
Mar-27-24 08:30AM	NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES (GlobeNewswire) +56.10%
Mar-21-24 08:30AM	LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments (GlobeNewswire)
Feb-27-24 08:30AM	Professor Ren Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research (GlobeNewswire) +20.81%
Feb-26-24 08:30AM	LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI (GlobeNewswire)
Jan-29-24 08:30AM	First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial (GlobeNewswire) +8.04%
Nov-13-23 08:30AM	LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations (GlobeNewswire)
Oct-16-23 08:30AM	LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration (GlobeNewswire) +9.54%
Oct-09-23 08:30AM	LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach (GlobeNewswire)
Sep-26-23 08:30AM	LIXTE Appoints Bas van der Baan as President and Chief Executive Officer (GlobeNewswire)
Sep-20-23 08:30AM	LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTEs First-in-Class PP2A Inhibitor, LB-100, Plus GSKs Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer (GlobeNewswire) +11.43%
Jul-20-23 04:05PM	LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -7.69% -7.89%
Jul-18-23 08:00AM	LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -31.47%
Jul-17-23 08:30AM	Preclinical Results of LIXTE Biotechnologys Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTEs Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy (GlobeNewswire) +38.67%
Jun-23-23 08:30AM	LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire)
Jun-07-23 08:30AM	LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTEs Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas (GlobeNewswire) -9.42%
Jun-05-23 09:41AM	Owning 53% in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) means that insiders are heavily invested in the company's future (Simply Wall St.)
Jun-02-23 12:30PM	LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023 (GlobeNewswire)
May-30-23 08:30AM	Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnologys Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy (GlobeNewswire)
Apr-24-23 08:30AM	LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma (GlobeNewswire)
Apr-04-23 08:30AM	LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hopes Ongoing Phase 1b Clinical Trial in Evaluating Lixtes Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer (GlobeNewswire) +7.03%
Feb-14-23 01:50PM	LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH (GlobeNewswire) +10.28%
Feb-08-23 05:26AM	Is Lixte Biotechnology Holdings (NASDAQ:LIXT) In A Good Position To Invest In Growth? (Simply Wall St.) -33.33%

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.

CEOMr. Geordan G. Pursglove

Chief Financial OfficerMr. Peter M. Stazzone

Chief Scientific OfficerMr. Bastiaan van der Baan M.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIXT

Lixte Biotechnology Holdings Inc

Upgrade your Finviz experience